Matrix metalloproteinases 2 and 9 are differentially expressed in patients with indeterminate and cardiac clinical forms of chagas disease

Infection and Immunity

Volumn 81, Issue 10, 2013, Pages 3600-3608

  Fares, Rafaelle Christine Gomes ^a   de Assis Silva Gomes, Juliana ^b   Garzoni, Luciana Ribeiro ^a   Waghabi, Mariana Caldas ^a   Saraiva, Roberto Magalhães ^c   Medeiros, Nayara Ingrid ^a   Oliveira Prado, Roberta ^a   Sangenis, Luiz Henrique Conde ^c   da Costa Chambela, Mayara ^c   de Araújo, Fernanda Fortes ^a   Teixeira Carvalho, Andréa ^a   Damásio, Marcos Paulo ^b   Valente, Vanessa Azevedo ^b   Ferreira, Karine Silvestre ^b   Sousa, Giovane Rodrigo ^b   da Costa Rocha, Manoel Otávio ^b   Correa Oliveiraa, Rodrigo ^d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

^d Instituto Nacional de Ciência e Tecnologia Doenças Tropicais INCT DT   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B;

ARTICLE; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; CONCENTRATION (PARAMETERS); CONGESTIVE CARDIOMYOPATHY; ELECTROCARDIOGRAM; ESOPHAGOGRAPHY; HUMAN; IMMUNOBLOTTING; INFLAMMATION; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORAX RADIOGRAPHY; ZYMOGRAPHY;

ADULT; AGED; BIOLOGICAL MARKERS; CHAGAS CARDIOMYOPATHY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED;

EID: 84884396796     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00153-13     Document Type: Article

References (49)

1. World Health Organization. August 2012. Fact sheet 340. World Health Organization, Geneva, Switzerland. http://www.who.int. Accessed 29 October 2012.
2. Moncayo A, Silveira AC. 2009. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem. Inst. Oswaldo Cruz 104(Suppl I):17-30.
3. Tanowitz HB, Machado FS, Jelicks LA, Shirani J, de Carvalho AC, Spray DC, Factor SM, KirchhoffLV, Weiss LM. 2009. Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Prog. Cardiovasc. Dis. 51:524-539.
4. Nunes MP, Colosimo EA, Reis RC, Barbosa MM, da Silva JL, Barbosa F, Botoni FA, Ribeiro AL, Rocha MO. 2012. Different prognostic impact of the tissue Doppler-derived E/e= ratio on mortality in Chagas cardiomyopathy patients with heart failure. J. Heart Lung Transplant. 31:634-641.
5. Rocha MO, Ribeiro AL, Teixeira MM. 2003. Clinical management of chronic Chagas cardiomyopathy. Front. Biosci. 1:44-54.
6. Rocha MO, Teixeira MM, Ribeiro AL. 2007. An update on the management of Chagas cardiomyopathy. Expert Rev. Anti Infect. Ther. 5:727-743.
7. Geurts N, Opdenakker G, Van den Steen PE. 2012. Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. Pharmacol. Ther. 133:257-279.
8. Parks WC, Wilson CL, Lopez-Boado YS. 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4:617-629.
9. Nagase H, Visse R, Murphy G. 2006. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69:562-573.
10. Hu J, Van den Steen PE, Sang QX, Opdenakker G. 2007. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6:480-498.
11. Kupai K, Szucs G, Cseh S, Hajdu I, Csonka C, Csont T, Ferdinandy P. 2010. Matrix metalloproteinase activity assays: importance of zymography. J. Pharmacol. Toxicol. Methods 61:205-209.
12. Li YY, McTiernan CF, Feldman AM. 2000. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc. Res. 46:214-224.
13. Vanhoutte D, Schellings M, Pinto Y, Heymans S. 2006. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc. Res. 69:604-613.
14. Polyakova V, Loeffler I, Hein S, Miyagawa S, Piotrowska I, Dammer S, Risteli J, Schaper J, Kostin S. 2010. Fibrosis in endstage human heart failure: severe changes in collagens metabolism and MMP/TIMP profiles. Int. J. Cardiol. 151:18-33.
15. Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy P, Schulz R. 2003. Matrix metalloproteinase-2 mediates cytokineinduced myocardial contractile dysfunction. Cardiovasc. Res. 57:426-433.
16. Opdenakker G, Van den Steen PE, Van Damme J. 2001. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 22:571-579.
17. Gutierrez FR, Lalu MM, Mariano FS, Milanezi CM, Cena J, Gerlach RF, Santos JE, Torres-Dueñas D, Cunha FQ, Schulz R, Silva JS. 2008. Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection. J. Infect. Dis. 197:1468-1476.
18. de Araújo FF, Corrêa-Oliveira R, Rocha MO, Chaves AT, Fiuza JA, Fares RC, Ferreira KS, Nunes MC, Keesen TS, Damasio MP, Teixeira-Carvalho A, Gomes JA. 2012. Foxp3+CD25(high) CD4+ regulatory T cells from indeterminate patients with Chagas disease can suppress the effector cells and cytokines and reveal altered correlations with disease severity. Immunobiology 217:768-777.
19. Gomes JA, Bahia-Oliveira LMG, Rocha MOC, Correa-Oliveira R. 2003. Evidence that development of severe cardiomyopathy in human Chagas disease is due to a non-balanced Th1 specific immune response. Infect. Immun. 71:1185-1193.
20. Chen QJ, Lu L, Peng WH, Hu J, Yan XX, Wang LJ, Zhang Q, Zhang RY, Shen WF. 2009. Polymorphisms of MMP-3 and TIMP-4 genes affect angiographic coronary plaque progression in non-diabetic and type 2 diabetic patients. Clin. Chim. Acta 405:97-103.
21. Meirelles MN, de Araujo Jorge TC, Miranda CF, de Souza W, Barbosa HS. 1986. Interaction of Trypanosoma cruzi with heart muscle cells: ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitro. Eur. J. Cell Biol. 41:198-206.
22. Garzoni LR, Adesse D, Soares MJ, Rossi MI, Borojevic R, de Meirelles MN. 2008. Fibrosis and hypertrophy induced by Trypanosoma cruzi in three-dimensional cardiomyocyte-culture system. J. Infect. Dis. 197:906-915.
23. Adesse D, Lisanti MP, Spray DC, Machado FS, Meirelles MN, Tanowitz HB, Garzoni LR. 2010. Trypanosoma cruzi infection results in the reduced expression of caveolin-3 in the heart. Cell Cycle 9:1639-1646.
24. de Oliveira FL, Araújo-Jorge TC, de Souza EM, de Oliveira GM, Degrave WM, Feige JJ, Bailly S, Waghabi MC. 2012. Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease. PLoS Negl. Trop. Dis. 6:e1696. doi:10.1371/journal.pntd.0001696.
25. Opdenakker G. 2001. New insights in the regulation of leukocytosis and the role played by leukocytes in septic shock. Verh. K. Acad. Geneeskd. Belg. 63:531-538.
26. Vandooren J, Geurts N, Martens E, Van den Steen PE, Opdenakker G. 2013. Zymography methods for visualizing hydrolytic enzymes. Nat. Methods 10:211-220.
27. Brunner S, Kima JO, Methe H. 2010. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. Am. J. Cardiol. 105:429-434.
28. Edsparr K, Basse PH, Goldfarb RH, Albertsson P. 2011. Matrix metalloproteinases in cytotoxic lymphocytes impact on tumour infiltration and immunomodulation. Cancer Microenviron. 4:351-360.
29. Gomes JA, Bahia-Oliveira LM, Rocha MO, Busek SC, Teixeira MM, Silva JS, Correa-Oliveira R. 2005. Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients. Infect. Immun. 73:7960-7966.
30. Souza PE, Rocha MO, Menezes CA, Coelho JS, Chaves AC, Gollob KJ, Dutra WO. 2007. Trypanosoma cruzi infection induces differential modulation of costimulatory molecules and cytokines by monocytes and T cells from patients with indeterminate and cardiac Chagas' disease. Infect. Immun. 75:1886-1894.
31. Mannello F, Medda V. 2012. Nuclear localization of matrix metalloproteinases. Prog. Histochem. Cytochem. 47:27-58.
32. Lockwood CJ, Oner C, Uz YH, Kayisli UA, Huang SJ, Buchwalder LF, Murk W, Funai EF, Schatz F. 2008. Matrix metalloproteinase 9 (MMP9) expression in preeclamptic decidua and MMP9 induction by tumor necrosis factor alpha and interleukin 1 beta in human first trimester decidual cells. Biol. Reprod. 78:1064-1072.
33. Deschamps AM, Spinale FG. 2006. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc. Res. 69:666-676.
34. Andrade JP, Marin-Neto JA, Paola AA, Vilas-Boas F, Oliveira GM, Bacal F, Bocchi EA, Almeida DR, Fragata Filho AA, Moreira MC, Xavier SS, Oliveira Junior WA, Dias JC. 2011. Sociedade Brasileira de Cardiologia. Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy. Chagásica Arq. Bras. Cardiol. 97(Suppl. 3):1-48. (In Portuguese.)
35. Menezes C, Costa GC, Gollob KJ, Dutra WO. 2011. Clinical aspects of Chagas disease and implications for novel therapies. Drug Dev. Res. Sep. 72:471-479.
36. Schulz R. 2007. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu. Rev. Pharmacol. Toxicol. 47:211-242.
37. Adair-Kirk TL, Senior RM. 2008. Fragments of extracellular matrix as mediators of inflammation. Int. J. Biochem. Cell Biol. 40:1101-1110.
38. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB. 2007. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur. Heart J. 28:711-718.
39. Gomes JA, Campi-Azevedo AC, Teixeira-Carvalho A, Silveira-Lemos D, Vitelli-Avelar D, Sathler-Avelar R, Peruhype-Magalhães V, Silvestre KF, Batista MA, Schachnik NC, Correa-Oliveira R, Eloi-Santos S, Martins-Filho OA. 2012. Impaired phagocytic capacity driven by downregulation of major phagocytosis-related cell surface molecules elicits an overall modulatory cytokine profile in neutrophils and monocytes from the indeterminate clinical form of Chagas disease. Immunobiology 217:1005-1016.
40. Keesen TS, Gomes JA, Fares RC, de Araújo FF, Ferreira KS, Chaves AT, Rocha MO, Correa-Oliveira R. 2012. Characterization of CD4(+) cytotoxic lymphocytes and apoptosis markers induced by Trypanossoma cruzi infection. Scand. J. Immunol. 76:311-319.
41. Clark RT, Nance JP, Noor S, Wilson EH. 2011. T-cell production of matrix metalloproteinases and inhibition of parasite clearance by TIMP-1 during chronic Toxoplasma infection in the brain. ASN Neuro. 3:1-12.
42. Reis DD, Jones EM, Chapadeiro E, Tostes S, Gazzinelli G, Colley DG, McCurley T. 1993. Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of TNF-alpha and dominance of granzyme A+, CD8+ lymphocytes. Am. J. Trop. Med. Hyg. 48: 637-644.
43. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. 2012. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin. Chim. Acta 413:656-662.
44. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. 2002. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 169:2643-2647.
45. Manque PA, Probst CM, Pereira MC, Rampazzo RC, Ozaki LS, Pavoni DP, Silva Neto DT, Carvalho MR, Xu P, Serrano MG, Alves JM, Meirelles MN, Goldenberg S, Krieger MA, Buck GA. 2011. Trypanosoma cruzi infection induces a global host cell response in cardiomyocytes. Infect. Immun. 79:1855-1862.
46. Aoki MP, Carrera-Silva EA, Cuervo H, Fresno M, Gironès N, Gea S. 2012. Nonimmune cells contribute to crosstalk between immune cells and inflammatory mediators in the innate response to Trypanosoma cruzi infection. J. Parasitol. Res. 2012:737324. doi:10.1155/2012/737324.
47. Spinale FG, Janicki JS, Zile MR. 2013. Membrane-associated matrix proteolysis and heart failure. Circ. Res. 112:195-208.
48. Matsunaga T, Abe N, Kameda K, Hagii J, Fujita N, Onodera H, Kamata T, Ishizaka H, Hanada H, Osanai T, Okumura K. 2005. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int. J. Cardiol. 105:203-208.
49. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR. 2006. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113:2089-2096.